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Models of normal physiology and disease are necessary in 
cancer research and clinical practice to optimally exploit the 
available (pre)clinical multi-scale and multi-modality data. 
Relevant models often cover multiple spatio-temporal scales 
and require automated access to heterogeneous and 
confidential data, making their development, validation and 
deployment challenging. 
The CHIC (Computational Horizons in Cancer) [1] project 
develops computational models for the cancer domain, as 
well as tools, services and a secure infrastructure for model 
and data access, and reuse. The architecture is designed to 
support the creation of complex disease models (hyper-
models) by composition of reusable component models (hypo-
models). It aims to provide individualized answers to 
concrete clinical questions by patient-specific 
parametrization of disease-specific hyper-models. 
We introduce the CHIC project and illustrate its approach to 
multi-scale cancer modelling by coupled execution of two 
component models operating on distinct spatial scales: 
- OncoSimulator (OS): a spatially discrete model of cancer 
cell proliferation and treatment effect in function of tumour, 
treatment and patient-specific parameters [2], implemented 
as cellular automaton model, 
- Bio-mechanical Simulator (BMS): a macroscopic continuum 
model of mechanical effects caused by tumour expansion in 
patient-specific anatomy, implemented as finite element 
model, based on [3]. 
Both component models exchange information about the 
spatial distribution of cancer cells and mechanical pressure in 
order to simulate the evolution of tumour volume and shape. 
Latter is achieved by correcting simple spherical growth (OS) 
by mechanically induced growth anisotropy (BMS). Results are 
demonstrated on the clinical example of Glioblastoma 
Multiforme. 
CHIC is working towards an extensible platform for in-silico 
oncology with a set of reusable component models at its 
core, covering sub-cellular, cellular and super-cellular scales. 
Viability of infrastructure and composite hyper-models is 
being evaluated against clinical questions in the treatment of 
Nephroblastoma, Glioblastoma and Non-small Cell Lung 
Cancer. 
 
Keywords: in-silico oncology, multi-scale modelling 
 
References: 
[1] http://www.chic-vph.eu/ 
[2] Stamatakos, G., 2011. In silico oncology: PART I Clinically 
oriented cancer multilevel 
modeling based on discrete event simulation. In: Deisboeck, 
T., Stamatakos, G. (Eds.), Multiscale Cancer Modeling. 
Chapman & Hall/CRC, Boca Raton, Florida, USA. 
[3] C. P. May, E. Kolokotroni, G. S. Stamatakos, and P. 
Büchler, ‘Coupling biomechanics to a cellular level model: An 
approach to patient-specific image driven multi-scale and 
multi-physics tumor simulation’, Progress in Biophysics and 
Molecular Biology, vol. 107, no. 1, pp. 193–199, Oct. 2011. 
 
2 
The symbiosis of science of radiation biology with 
immunology: Impact on basic and translational research 
M. M. Ahmed 
Molecular Radiation Therapeutics Branch, Radiation Research 
Program, National Cancer Institute (NCI), NIH, Rockville, MD 
20850 
 
Recent evidence indicates that radiation is potent modulator 
of immune system.  The field of radiation biology and 
immunology is at crossroads in cancer research.  With this 
amalgamation, new clinical trials have emerged combining 
radiation therapy with immune modulating agents.  Through 
this partnership, there is a promise to augment higher 
progression survival benefit than cancer immunotherapy as 
monotherapy. Merger of two fields can generate provocative 
themes that need the minds of basic immunologist to interact 
with radiation biologists to define radiation dose exposure, 
types of radiation, sequencing and dosing of vaccination and 
immune modulation biomarkers.  Further, radiation biologist 
can learn from immunologist on what animal models can be 
utilized for primary and metastatic tumors.   As the synergy 
is happening now between these two fields, there is greater 
focus in developing immune modulating agents for adjuvants 
to radiotherapy of solid tumors.  This area is maturing for 
better understanding of the mechanistic actions of in-situ 
radiation vaccine.  With this advent of advancement, there 
are vast opportunities to understand effects of radiation on 
tumor and normal tissue and how this damage cooperates 
with the host immune activation and injury.  Such 
understanding can lead to identification of immune 
biomarkers that can be utilized in immune monitoring in 
tumor control and potentially synergize with other markers 
of normal tissue damage.  This talk will focus on 
understanding the response of some key components of 
tumor immune microenvironment to radiation such as 
regulatory T-cells and myeloid cells in regulating 
immunogenic tumor cell death. The other focus will include 
how host immune machinery reacts to normal tissue injury 
and further any immune biomarkers can be validated for 
immune monitoring in clinical trials.   
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Heavy and quite expensive afterloaders with iridium sources 
are now widely used for the HDR brachytherapy of tumors. 
The cost of this kind of treatment, as well as the necessity of 
heavily shielded canyons and of special technology of source 
delivery and replacement, makes the brachytherapy with 
iridium sources less widespread. Moreover, the relatively 
hard radiation of iridium-192 often makes damage to healthy 
organs close to a tumor. 
These problems of HDR brachytherapy can be resolved with 
ytterbium sources. Compared to other isotopes used for HDR 
brachytherapy, the isotope Yb-169, having the average 
photon emission energy of 93 KeV, requires a much lighter 
shielding.  For example, the tungsten shield of only 2-3 cm 
makes the HDR therapeutic ytterbium source harmless for the 
personnel. Therefore a source loader with ytterbium sources 
may be a compact and cheap desktop device. Moreover, the 
treatment quality may be significantly improved due to 
ytterbium radiation collimation. In the figure we compare 
two ytterbium dose distributions in water: one behind the 
tungsten layer of 2 mm (lower line) and the other without it. 
It follows form this figure that only 2 mm of tungsten allow 
to effectively collimate the ytterbium source radiation – the 
suppressed dose is 30 times lower! This also means that a 
new cheep and accurate preloader, let’s call it an 
“acculoader”, with a hidden ytterbium source inside can be 
easily manufactured. In this case the target irradiation will 
begin just by the source pushing forward.    
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We created an AVLIS facility for the production of primary 
isotope Yb-168 with the enrichment above 20% and with a 
record capacity.  In order to increase the activity and 
improve mechanical properties of ytterbium sources, we 
developed the technology of ytterbium ceramics production. 
The design of new compact source loader with ceramic 
ytterbium sources is now in progress.    
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In proton therapy, as well as in carbon ion therapy, two main 
methods of dose distribution formation can be used: the 
passive particle scattering and the particle scanning in 
several modifications. The pencil-beam scanning is now 
considered as a most advantageous method of dose 
distribution formation. Indeed, this method provides the 
conformance of dose delivery to a tumor of any size with no 
significant dose, delivered to healthy surrounding tissue. 
However, in some cases the beam scanning method may have 
problems. In particular, this is the case of small targets when 
the pencil beam width is comparable with the target size. 
The eye melanoma and small brain metastasis may be 
examples of such small tumors.  
In these cases the application of the old method of passive 
beam scattering with a formation of individual dose 
distributions may be reasonable. However, this method in its 
classical version with a ridge filter, a bolus and a collimator 
is known to fail to provide the sufficiently conformal dose 
distribution with one field: either the maximal dose 
significantly exceeds the tumor volume on its proximate site 
or the dose value changes too much within the tumor 
volume.  
We found a new construction of a two-component ridge filter 
which provides the dose distributions with no mentioned 
above shortcomings (the corresponding patent is pending).  
We have performed a series of calculations with the help of 
the original Monte-Carlo code SRNA in order to find the 
optimal construction of new ridge filters from the point of 
view of dose distribution accuracy and of the device 
manufacturability. In the figure the example of dose 
distribution calculated with the SRNA program is presented. 
As it follows from the figure, even with one field the 95% 
isodose line does not notably leave the tumor volume, 
represented by the black circle. The usual “wings” on 
proximate side of lower isodose lines are absent as well.  The 
experimental tests of these new devices with proton beams 
of the INR linac are now in progress. 
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Purpose: Recently, the interest of using hadron-therapy in 
cancer treatment, particularly for tumors in the vicinity of 
critical organs-at-risk, has grown due to the ability of 
providing high precision dose delivery. In order to fully 
exploit this feature, a precise monitoring of particle beam 
(proton, ions) is mandatory. Therefore, the purpose of our 
project is to develop an online imaging system based on a 
Compton camera to verify the particle beam (proton, ions) 
range by detecting prompt γ rays, induced as a result of 
nuclear reactions between the particle beam and biological 
tissue. 
Material / Methods: The Compton camera consists of two 
main components: a scatterer (tracker), formed by a stack of 
six customized double-sided Si-strip detectors (DSSSD), and a 
monolithic LaBr3 scintillation detector (50x50x30 mm3) acting 
as an absorber detector. The DSSSD detector is processed by 
a compact ASIC based electronics, while the LaBr3 detector is 
read out by a position-sensitive (16x16) multi-anode 
photomultiplier (PMT, Hamamatsu H9500), whose segments 
are processed individually using spectroscopy electronics. 
The energy and timing signals are digitized in a VME-based 
charge-to-digital converter and time-to-digital converter, 
respectively. 
Results: The Compton camera components have been 
characterized in the laboratory using calibration sources. The 
time and energy resolution of the LaBr3 detector were 
measured to be 273 ± 6 ps (FWHM) and 3.5%, using 60Co and 
